Interview with Germano Carganico, General Manager, Toscana Life Sciences
Italians are often praised to make up deficiencies of the country at national level with more creativity at a regional level- which is why Science Parks are coordinated at the…
Address: Via Fiorentina, 1 , 53100 Siena,Italy
Tel: +39 0577 231211
Web: http://www.toscanalifesciences.info/it/
Toscana Life Sciences (TLS) consists of both a Science park and a foundation.
TLS foundation is a non-profit organization founded in December 2004 by a group of public and private institutions in Tuscany, including the Province and Municipality of Siena, the Tuscany Region, the Monte Paschi Bank and Monte Paschi Foundation, the Chamber of Commerce of Siena, the Universities of Florence, Siena and Pisa, the Scuola Normale and Scuola St. Anna of Pisa, and the Hospital of Siena.
The Science Park represents the most important project of the TLS Foundation; its main aim is to offer equipped buildings, services and financing opportunities, thus creating a fertile ground for the development of new biotech companies focused on pharmaceutical, biotech, diagnostic and innovative biomedical technologies.
Besides the equipped labs and office rental, the TLS Science Park provides incubated companies with a full package of services, ranging from General Services, linked to day-to-day research activities, to Consultancy Services in line with company business management needs.
Italians are often praised to make up deficiencies of the country at national level with more creativity at a regional level- which is why Science Parks are coordinated at the…
Top recent stories from Italian pharma, including Angelini’s EUR 150 million EU collaboration for European health startups, Chiesi’s new deals for enzyme replacement therapies and gene editing, and why Menarini…
Writing in the June 2025 edition of DIA’s Global Forum Magazine, Finn McCartney, Maria Dutarte, Petra Adámková, and Paola Kruger from the European Patients’ Academy on Therapeutic Innovation (EUPATI) weigh…
Banking on three key therapeutic areas, including a newly established rare disease franchise, the Italian midcap Chiesi has pursued a sweeping transformation in recent years. In its reboot efforts, the…
A roundup of some of the biggest pharma and healthcare stories coming out of Italy, including the country’s ever-falling birth rate; Chiesi’s new manufacturing investment; Doc Generici’s rebrand to DOC…
Some of the biggest pharma and healthcare stories coming out of Italy, including Italy’s antitrust investigation of Novartis and Genentech; Johnson & Johnson’s EUR 125 million investment in its Italian…
A roundup of some of the biggest stories from Italian pharma and healthcare, including Italfarmaco’s FDA approval for its DMD treatment; Alfasigma’s acquisition of Galapagos’s Jyseleca, the antibiotics deal between…
The grants and loans allocated by the European Union’s Recovery and Resilience Facility (RRF), a large part of which have been assigned to healthcare, set out to mitigate the economic…
After former CEO Pierluigi Antonelli abruptly announced his departure last month, the Italian mid-cap has signed on former Gilead leader, Jacopo Andreose, as its new chief executive. [I am]…
Angelini Pharma CEO Pierluigi Antonelli has announced that he is leaving his position with immediate effect, posing the question of what comes next for the leading Italian mid-cap. Antonelli,…
The electoral victory of the centre-right coalition in Italy should see far-right firebrand Giorgia Meloni replace former European Central Bank President Mario Draghi as Prime Minister at the end of…
Digitalisation has become a buzz word in in the global life sciences sector. In Italy, digital transformation has taken on special significance as one of the principal goals encompassed in…
The Italian system requires drug companies to go through approvals at a national level with the Italian Medicines Agency (AIFA), only to then confront the country’s 21 regional authorities who…
See our Cookie Privacy Policy Here
